CC
BIOSW

Centiva Capital’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

Centiva Capital’s Portfolio BIOSW Stock Details BIOSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$7K – 1940
2022
Q2 		$7K Hold
50,000
– – ﹤0.01% 1560
2022
Q1 		$11K Buy
+50,000
New +$13K ﹤0.01% 1526

Other funds holding BIOSW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Centiva Capital's BIOSW Position: Q3 2022 in Review

Centiva Capital sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q3 2022, closing a stake of 50,000 shares — an estimated $7K sold.

Centiva Capital first reported a position in BIOSW in Q1 2022 and held it in 2 quarters. The position peaked at $11K in Q1 2022. 49 funds tracked by Wall St. Rank hold BIOSW as of Q3 2022.

  • Centiva Capital reported no remaining BioPlus Acquisition Corp. Warrants position as of Q3 2022 after selling out during the quarter.
  • Centiva Capital sold 50,000 BioPlus Acquisition Corp. Warrants shares in Q3 2022, an estimated $7K.
  • Centiva Capital first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 2 quarters.
  • Centiva Capital's BioPlus Acquisition Corp. Warrants position peaked at $11K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q3 2022.

Based on Centiva Capital's 13F filing for Q3 2022, filed 14 Nov 2022.